Pure Global

ALS Phase II Study of NX210c - Trial NCT06365216

Access comprehensive clinical trial information for NCT06365216 through Pure Global AI's free database. This Phase 2 trial is sponsored by Axoltis Pharma and is currently Not yet recruiting. The study focuses on Amyotrophic Lateral Sclerosis. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06365216
Phase 2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06365216
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
ALS Phase II Study of NX210c
A Double-blind, Randomized, Placebo-controlled, Multicentric, Phase II Study in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Multiple Intravenous Infusions of NX210c

Study Focus

NX210c

Interventional

drug

Sponsor & Location

Axoltis Pharma

Bron, France

Timeline & Enrollment

Phase 2

Sep 01, 2024

Feb 01, 2026

80 participants

Primary Outcome

The effect of NX210c on blood neurofilament light chain (NfL) or on a blood and cerebrospinal fluid (CSF) biomarker of BBB integrity.

Summary

This study will investigate the efficacy, safety, tolerability and pharmacokinetics (PK) of
 multiple intravenous infusions of NX210c, at two dose levels, in patients with Amyotrophic
 lateral sclerosis (ALS).

ICD-10 Classifications

Neuralgic amyotrophy
Motor neuron disease
Other degenerative diseases of the nervous system
Other degenerative disorders of nervous system in diseases classified elsewhere
Multiple sclerosis

Data Source

ClinicalTrials.gov

NCT06365216

Non-Device Trial